“…Out of the 38 studies selected for review, 60.5% (n = 23) analyzed the EFSA (Aggett, 2007(Aggett, , 2009(Aggett, , 2012Asp & Bryngelsson, 2008;Biesalski, Aggett, & Anton, 2011;Buttriss, 2010;Buttriss & Benelam, 2010;Coppens, 2009Coppens, , 2010Flynn, 2011;Gilsenan, 2011;Gorny, 2012;Kardinaal, Mennen, & Hendriks, 2009;Lalor & Wall, 2012;Mitchell, Aggett, Richardson, Stowell, 2011;O'Connor, 2011;Reuterswärd, 2007;Richardson, 2012;Vero & Gasbarrini, 2012;Walter, 2009;Pravst, 2012;Meisterernst & Haber, 2007;Gallagher, Meijer, & Richardson, 2011); a total of 23.7% (n = 9) analyzed the FDA (Aggett, Hathcock, & Jukes, 2012;Ellwood et al, 2010;FDA, 2009;Guzelian & Guzelian, 2008;Hasler, 2008;Kuhn, 2008;Lupton, 2009;Schneeman, 2007Schneeman, , 2010 and 15.8% (n = 6) were comparative analyses of both agencies (Binns, 2008;Jovicic et al, 2011;Lalor & Wall, 2011;Martin, 2010;Moors, 2012;Verhagen, Vos, Franch, Heinonen, & van Loveren, 2010). Of the authors whose articles were selected for review, only four were somewhat affiliated with the agencies they analyzed …”